Wall Street analysts expect Biogen Inc. (BIIB) to post quarterly earnings of $3.16 per share in its upcoming report, which indicates a year-over-year decline of 22%. Revenues are expected to be $2.46 billion, down 3.4% from the year-ago quarter.Over the last 30 days, there has been a downward revision of 0.4% in the consensus EPS estimate for the quarter, leading to its current level. This signifies the covering analysts' collective reconsideration of their initial forecasts over the course of this timefram ...

Biogen Inc. (BIIB) is expected to deliver a year-over-year decline in earnings on lower revenues when it reports results for the quarter ended December 2023. This widely-known consensus outlook gives a good sense of the company's earnings picture, but how the actual results compare to these estimates is a powerful factor that could impact its near-term stock price.The earnings report, which is expected to be released on February 13, 2024, might help the stock move higher if these key numbers are better than ...

In the latest trading session, Biogen Inc. (BIIB) closed at $243.72, marking a -1.66% move from the previous day. The stock's change was less than the S&P 500's daily gain of 1.07%. Meanwhile, the Dow gained 0.35%, and the Nasdaq, a tech-heavy index, added 1.74%.The company's shares have seen a decrease of 4.78% over the last month, not keeping up with the Medical sector's gain of 4.02% and the S&P 500's gain of 2.93%.The upcoming earnings release of Biogen Inc. will be of great interest to investors. The c ...

Biogen Inc. (BIIB) announced plans to reprioritize its resources in Alzheimer’s disease (AD). It intends to advance the new Alzheimer’s drug Leqembi (lecanemab-irmb) and to accelerate the development of new treatment modalities.Alzheimer's is a progressive, fatal disease of the brain characterized by a decline in memory, language and other thinking skills, as well as changes in mood and behavior.As part of this reprioritization plan, Biogen will henceforth stop the development and commercialization of its c ...

Biogen on Wednesday said it will discontinue the sale and development of its older and highly controversial Alzheimer's drug Aduhelm to refocus the company's efforts to treat the memory-robbing disease. The biotech company will focus on rolling out Leqembi, a newly approved Alzheimer's drug it developed with the Japanese drugmaker Eisai. It also plans to work on a slate of experimental treatments for the disease. Those drugs represent a new chapter for the company after the polarizing launch and approval of ...

Biogen Inc. BIIB, -0.18% said Wednesday that it will halt the development and commercialization of its Alzheimer’s drug Aduhelm, which drew intense scrutiny of its U.S. regulatory approval process due to concerns about whether its benefits outweighed its risks. The drugmaker said it will continue to advance Leqembi, the Alzheimer’s treatment granted full approval last year by the U.S. Food and Drug Administration and will accelerate development of other potential new treatments. The decision to discontinue ...

Company to reprioritize resources allocated to ADUHELM® (aducanumab-avwa) to advance LEQEMBI® (lecanemab-irmb) and to develop new treatment modalitiesBiogen committed to building a leading Alzheimer's disease franchise to address patient needs CAMBRIDGE, Mass., Jan. 31, 2024 (GLOBE NEWSWIRE) -- Biogen Inc. (NASDAQ:BIIB) today announced plans to reprioritize its resources in Alzheimer's disease (AD), a strategic therapeutic area expected to drive near and long-term growth. The company will continue to advanc ...

In the latest market close, Biogen Inc. (BIIB) reached $247.52, with a +1.1% movement compared to the previous day. This change outpaced the S&P 500's 0.76% gain on the day. Elsewhere, the Dow gained 0.59%, while the tech-heavy Nasdaq added 1.12%.Shares of the company have depreciated by 5.39% over the course of the past month, underperforming the Medical sector's gain of 1.57% and the S&P 500's gain of 2.5%.The upcoming earnings release of Biogen Inc. will be of great interest to investors. The company's e ...

Core Insights - Biogen Inc. has a strong track record of beating earnings estimates, with an average surprise of 7.95% over the last two quarters [1] - The most recent earnings report showed a surprise of 9.27%, with actual earnings of $4.36 per share compared to an expectation of $3.99 per share [1] - The previous quarter also exceeded expectations, reporting $4.02 per share against a consensus estimate of $3.77 per share, resulting in a surprise of 6.63% [1] Earnings Estimates and Predictions - Estimates for Biogen Inc. have been trending higher, influenced by its history of earnings surprises [2] - The stock has a positive Zacks Earnings ESP of +2.67%, indicating recent bullish sentiment among analysts regarding the company's earnings prospects [3] - The combination of a positive Earnings ESP and a Zacks Rank of 3 (Hold) suggests a high likelihood of another earnings beat, with historical data showing nearly 70% success in similar scenarios [2][3] Upcoming Earnings Report - Biogen Inc. is expected to release its next earnings report on February 13, 2024 [3]

In the latest trading session, Biogen Inc. (BIIB) closed at $251.68, marking a +1.36% move from the previous day. This move outpaced the S&P 500's daily gain of 0.29%. Meanwhile, the Dow experienced a drop of 0.25%, and the technology-dominated Nasdaq saw an increase of 0.43%.Heading into today, shares of the company had lost 3.75% over the past month, lagging the Medical sector's gain of 2.29% and the S&P 500's gain of 2.08% in that time.The upcoming earnings release of Biogen Inc. will be of great interes ...